Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

ts) for those that received standard chemotherapy.

"It is gratifying that we are seeing more patients convert to complete remission after the initial assessment period with pixantrone compared to other agents. These additional late responders are likely to have a positive impact on analyses of progression free and overall survival and will be provided to the U.S. Food and Drug Administration during the 120-day update," stated James A. Bianco, M.D., Chief Executive Officer of CTI. "We plan to request priority review of the NDA from the FDA as we believe that pixantrone would provide patients and physicians with a compelling new option in treating this disease."

Review of Pixantrone Clinical Studies in Indolent non-Hodgkin's lymphoma

Additionally, data from two previously reported clinical trials investigating pixantrone combined with other agents in indolent NHL is being reviewed. In one trial, PIX 302, patients that received pixantrone plus rituximab achieved higher CR and ORR rates, (CR=35% (7 of 20 patients); ORR=75% (15 of 20 patients)) as well as a longer TTP (13.2 months) than those who only received rituximab alone (CR=11% (2 of 18 patients); ORR=33% (6 of 18 patients); TTP=8.1 months) in relapsed/refractory indolent NHL. In a separate study, AZA I06, pixantrone and the FPD-R regimen achieved high response rates (CR/CRu=70% (19 of 27 patients); ORR=89% (24 of 27 patients) in relapsed/refractory indolent NHL, nearly all of whom had received aggressive first-line therapy with CHOP-R.

The Pan Pacific Lymphoma Conference poster is available at http://www.celltherapeutics.com/investor_updates.

About the PIX 301 EXTEND Trial

The PIX 301 EXTEND trial was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Siemens Healthcare addresses the clinical and business ... Session of the American College of Cardiology (ACC), March ... a commitment to excellence, Siemens empowers its customers with the ... and help them meet their strategic and metric goals. Siemens, ...
... Tenn. , March 12 Brad Tice , Pharm.D., Chief Clinical Officer of PharmMD, will receive the 2010 APhA-APPM Distinguished ... be held in Washington, D.C. on March 12-15, 2010 . , ... ... ...
Cached Medicine Technology:Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 2Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 3Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 4Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 5Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 6Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 7Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 8Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 9Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 10Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 11Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 12Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 13Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 14PharmMD's Brad Tice to Receive Distinguished Achievement Award 2PharmMD's Brad Tice to Receive Distinguished Achievement Award 3PharmMD's Brad Tice to Receive Distinguished Achievement Award 4PharmMD's Brad Tice to Receive Distinguished Achievement Award 5
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... Johnston, whose work has transformed cancer care in Northern ... European Academy of Cancer Sciences., The Academy, which was ... highly distinguished oncologists and cancer researchers which aims to ... Europe. , Professor Johnston, whose leadership has seen cancer ... of the UK league table to near the top, ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
(Date:4/15/2014)... frozen fish caused nearly half of all injuries aboard ... on freezer-longliner vessels operating off the coast of Alaska, ... of those injuries and others aboard the two types ... and the research methods used in the study could ...
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight on ... in other areas of the world, which may have limited ... successful interventions. , A report on the global AIDS ... the HIV/AIDS pandemic, which has left 12 million children orphaned ...
Breaking Medicine News(10 mins):Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Changes in processing, handling could reduce commercial fishing injuries 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3
... BEACH, Calif., May 1 With the world gripped by ... epidemic, how can people be adequately prepared for the dangers ... Newport Beach psychologist, says, "People need to be informed, prepared, ... in this moment." People are obsessing over the swine ...
... HULL, England, May 1 Smith & Nephew,s Advanced Wound Management ... Patents Court, in the High Court of Justice of England and ... asserted against Smith & Nephew of the Negative Pressure Wound Therapy ... (KCI) (NYSE: KCI ). The 3 other claims ...
... The Quigley Corporation, (Nasdaq: QGLY ) ... of $4.0 million, for the first quarter ended March 31, 2009, ... decrease in net sales for the first quarter of 2009 reflects ... reported by Information Resources Inc., ("IRI") data, general economic weakness and ...
... 1 Gaiam, Inc. (Nasdaq: GAIA ), ... products and services to customers who value personal development, ... announce results for the first quarter ended March 31, ... 6, 2009. The Company will hold a teleconference to ...
... to $2.70 - $2.85 per Diluted ShareVIRGINIA BEACH, Va., May 1, ... that its net income for the first quarter of 2009 increased ... income of $33.6 million, or $0.62 per diluted share, for the ... , ...
... fitness, and performance services, recently supported Global Medical Brigades on a ... ... Brook, IL (PRWeb) May 1, 2009-- AthletiCo , an Illinois-based ... Medical Brigades on a medical mission trip to Honduras. ...
Cached Medicine News:Health News:How to Be Prepared for, but Not Paralyzed by Fear of, the Swine Flu Epidemic 2Health News:Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision 2Health News:Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision 3Health News:The Quigley Corporation Reports First Quarter 2009 Results 2Health News:The Quigley Corporation Reports First Quarter 2009 Results 3Health News:The Quigley Corporation Reports First Quarter 2009 Results 4Health News:The Quigley Corporation Reports First Quarter 2009 Results 5Health News:The Quigley Corporation Reports First Quarter 2009 Results 6Health News:The Quigley Corporation Reports First Quarter 2009 Results 7Health News:The Quigley Corporation Reports First Quarter 2009 Results 8Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 2Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 3Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 4Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 5Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 6Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 7Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 8Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 9Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 10Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 11Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 12Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 13Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 14Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 15Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 16Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 17Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 18Health News:AthletiCo Employees Volunteer Time And Talent To Support Global Medical Brigades 2Health News:AthletiCo Employees Volunteer Time And Talent To Support Global Medical Brigades 3
... Sequenza Slide Rack works hand in ... you an organized, reliable method for immunostaining. ... Coverplate system which ensures consistency and excellent ... large immuno runs (up to 50 slides/run) ...
Inquire...
ISI Micro Brushes are available in a variety of French diameters. Made with stainless steel handles and nylon bristles, the ISI Micro Brushes will last through countless cleanings....
... Novas Point-of-Care Manager is ... gas and critical care ... the industry. PDM ... workstation designed to effortlessly ...
Medicine Products: